Last Updated: 14 January 2025
FIZE Medical has successfully closed a $30 million Series A funding round, which includes a $14 million Series A-4 segment. This milestone highlights the company’s position as a leader in fluid management technology.
The Series A-4 financing round was led by Rapha Capital Management, supported by Valitas Venture Capital and eHealth Ventures.
Managing fluid levels in intensive care units (ICUs) is a critical challenge. In the U.S., over 4 million ICU patients are hospitalized annually. Among them, one-third experience circulatory shock, a life-threatening condition with a 40% mortality rate. Meanwhile, nearly 50% develop acute kidney injury (AKI), which has mortality rates exceeding 20%.
FIZE Medical’s FIZE-kUO® device offers an innovative solution. By delivering real-time kidney function monitoring, the device provides minute-by-minute updates to clinicians.
This approach empowers healthcare teams to detect problems early and act fast, significantly improving outcomes.
"We are thrilled to have Rapha Capital as the lead investor in this funding round, reaffirming their commitment to our mission. This funding, alongside support from Valitas Venture Capital, eHealth Ventures, and our existing investors, will enable us to accelerate our expansion into the U.S. and EU healthcare markets. With our innovative fluid management solutions, we look forward to positively impacting more hospitals and patients globally."
Dror Zerem, CEO of FIZE Medical
FIZE Medical plans to use the funding to expand into the U.S., EU, and Asian markets. Scaling production is a top priority, with operations bolstered by partnerships such as those with Cicor facilities in Vietnam. These steps ensure the company can meet growing demand efficiently.
The company is also improving its AI-driven platform. New features, including predictive capabilities for early detection of critical conditions and better integration with electronic medical records (EMRs), will further optimize patient care.
Over the next year, FIZE Medical aims to launch innovative tools such as intra-abdominal pressure monitoring and advanced AI for condition prediction. These updates are set to raise the bar for fluid management technology worldwide.
FIZE Medical is a forward-thinking company specializing in fluid management technology powered by artificial intelligence. Their solutions address pressing needs in critical care.
The company was founded to revolutionize ICU care. CEO Dror Zerem leads a team dedicated to advancing healthcare, including Chief Commercial Officer Sima Faifman Kuchersky.
Key board members include representatives from Rapha Capital, Valitas Venture Capital, and eHealth Ventures. These experts bring deep experience in MedTech and innovation, strengthening FIZE Medical’s strategic direction.
At the heart of their innovation is the FIZE-kUO® device, which provides unparalleled real-time monitoring. By delivering actionable data, it empowers clinicians to take proactive steps, improving patient outcomes and optimizing healthcare systems globally.
